HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals (RIA)

The call opens on 29th October 2026

HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics (IA)

The call opens on 29th October 2026

Deadline of second stage is 16th September 2027

HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications (RIA)

The call opens on 29th October 2026 

HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential (RIA)

HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses (RIA)

HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses (RIA)

HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials (RIA)

HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD) (RIA)

The call opens on 29th October 2026 

HORIZON-BRIDGING-2027-04-03 Bringing innovative climate preparedness and resilience solutions closer to the market
 

The aim of this EUP OHAMR call supports international research collaborations aimed at improving our understanding of antimicrobial resistance (AMR) transmission and developing effective strategies to prevent its emergence and spread across the One Health spectrum.

Topic 1: Model AMR transmission dynamics to predict the risk of AMR emergence and spread to support decision-making of public authorities.

Topic 2: Understand and characterise the role of host commensal micro-organisms (including fungi) in AMR dynamics and develop solutions aiming at selective decolonising of resistant organisms in the host (human and animals) to prevent transmission.

Topic 3: Develop or improve tools and methods to reduce resistant bacteria, fungi, and resistance genes in environmental hotspots, and investigate the impact of these tools and methods on AMR transmission.

The call aims to support collaborative research into recently identified rare diseases that remain poorly understood, helping to build the knowledge base needed for future therapeutic development.

The call opens on 1st December 2026. The on-line info seminar will be held on 14th December 2026

HORIZON-BRIDGING-2027-02-05 Advancing promising results from Pillar II collaborative research through the innovation journey
The call will open on 20th October 2026; deadline of the call is 28th January 2027

This joint transnational call aims to support implementation-oriented research and innovation that accelerates the uptake, adaptation, testing, evaluation and scaling of evidence-informed approaches to health and care workforce transformation.

The call opens on 16th November 2026. The on-line info seminar will be held on 2nd December 2026.

EP PerMed will fund research and innovation projects in Cell and Gene Therapy for Personalised Medicine.

This is a 2-stage call. The 20th January 2027 is deadline for 1st stage proposals.

Pre-proposal

ERA4Health's ninth Joint Transnational Call (JTC9),   IICS4all 2027,  will support multinational interventional investigator-initiated clinical studies addressing cardiovascular, metabolic, autoimmune and non-communicable respiratory diseases.

The call aims to generate high-quality clinical evidence through pragmatic, phase III, multinational interventional studies, while ensuring  inclusivity and diversity in the study population and including sex/gender-sensitive, age-specific or other diversity-related aspects in the study.  The call will support comparative-effectiveness studies and drug repurposing approaches involving approved off-patent medicines.

The call opens on 27th October 2026

Pre-proposal

ERA4Health's ninth Joint Transnational Call (JTC10),   NanoDiagNCD 2027,  will support research on nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of noncommunicable diseases

The aim of this call is to support translational research projects that develop application(s) of nanotechnologies, either solely or in combination with Key Enabling Technologies (KETs), to make significant strides in the development of diagnostic and theranostic tools for Non-Communicable Diseases (NCDs).

The call opens on 17th November 2026; on-line info-day will be held on 19th November 2026

Demonstrating place-based experimentation and innovation spaces as enabling environments for scaling EU Missions
HORIZON-MISS-2026-07-CROSS-04

The ISIDORe II project invites applications for free-of-charge Transnational Access (TNA) to research infrastructure services supporting Andes virus (ANDV) and ANDV-relevant hantavirus research.

Innowwide is a mono beneficiary programme. The programme supports the organisation in the EU member state, Iceland, Israel, Norway, Switzerland, Türkiye, or United Kingdom, but entities in target countries that SMEs choose to collaborate with can benefit indirectly as subcontractors. The subcontractors are not party to the grant agreement i.e., they do not have a contractual relationship with the Funding Authority.

A market feasibility project includes preliminary technical, market, legal and/or socioeconomic assessments intended to validate the feasibility of your international and innovative business solution (product-, process- or service-market combination) within new and emerging global value chains.

The innovation to be explored in the market feasibility project must have a minimum Technology Readiness Level (TRL) of 4, meaning it has been validated in a laboratory or relevant environment and is ready for initial application or demonstration. The TRL of that innovation must not exceed 8 in your target country. Where further R&I activities are expected, TRL 7 is the indicative top limit.